Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XLV constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | GEHC | GE HealthCare Technologies Inc. Common Stock | 71.0 | 8.16% | 0.60 | 30 | -11.89% | 12 | grey |
| 2 | COO | The Cooper Companies, Inc. Common Stock | 60.9 | 5.64% | 0.27 | 16 | -29.82% | 26 | safe |
| 3 | MTD | Mettler-Toledo International | 60.6 | 3.93% | 1.09 | 31 | -11.10% | 16 | safe |
| 4 | IDXX | Idexx Laboratories Inc | 60.2 | 3.36% | 1.34 | 35 | -11.59% | 23 | safe |
| 5 | ALGN | Align Technology Inc | 58.1 | 5.68% | 0.30 | 38 | -12.88% | 40 | safe |
| 6 | AMGN | Amgen Inc | 57.7 | 4.27% | 0.72 | 34 | -9.15% | 32 | grey |
| 7 | STE | STERIS plc | 55.6 | 4.56% | 0.29 | 33 | -9.95% | 8 | safe |
| 8 | SYK | Stryker Corporation | 55.4 | 4.17% | 0.45 | 33 | -18.30% | 25 | safe |
| 9 | BMY | Bristol-Myers Squibb Co. | 52.4 | 6.06% | 0.63 | 45 | +0.08% | 56 | safe |
| 10 | DVA | DaVita Inc. | 52.4 | 9.27% | 0.55 | 53 | +3.52% | 72 | grey |
| 11 | BSX | Boston Scientific Corp. | 51.5 | 4.86% | 0.49 | 43 | -12.64% | 31 | safe |
| 12 | ZTS | ZOETIS INC. | 50.9 | 9.40% | 0.43 | 44 | -0.57% | 28 | safe |
| 13 | UNH | UNITEDHEALTH GROUP INCORPORATED (Delaware) | 49.5 | 4.93% | 0.38 | 40 | -5.43% | 45 | safe |
| 14 | ABT | Abbott Laboratories | 48.7 | 3.78% | 0.39 | 38 | -8.34% | 16 | safe |
| 15 | INCY | Incyte Genomics Inc | 47.0 | 7.79% | 0.34 | 46 | -0.03% | 34 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | HSIC | Henry Schein Inc | 56.9 | 8.37% | 9.05 | -2.16% | high |
| 2 | RMD | ResMed Inc. | 54.8 | 9.09% | 8.94 | -1.33% | high |
| 3 | DVA | DaVita Inc. | 53.4 | 7.45% | 8.21 | +3.52% | high |
| 4 | INCY | Incyte Genomics Inc | 49.5 | 5.63% | 7.69 | -0.03% | elevated |
| 5 | BIIB | Biogen Inc. Common Stock | 49.5 | 3.88% | 8.66 | +2.06% | elevated |
| 6 | ELV | Elevance Health, Inc. | 46.3 | 2.53% | 6.56 | +5.85% | elevated |
| 7 | MRNA | Moderna, Inc. Common Stock | 45.6 | 10.84% | 1.00 | +129.92% | elevated |
| 8 | GEHC | GE HealthCare Technologies Inc. Common Stock | 43.8 | 4.16% | 7.50 | -11.89% | elevated |
| 9 | ZBH | Zimmer Biomet Holdings, Inc. | 43.2 | 4.57% | 6.48 | -1.91% | elevated |
| 10 | BDX | Becton, Dickinson and Co. | 41.8 | 3.89% | 6.12 | -1.00% | elevated |
| 11 | UHS | Universal Health Services, Inc. Class B | 41.8 | 6.23% | 4.00 | +0.49% | elevated |
| 12 | WST | West Pharmaceutical Services, Inc. | 41.5 | 3.14% | 4.89 | +0.47% | elevated |
Market cap, valuation, and short-interest metrics are joined to the latest XLV holdings snapshot; each ticker links to its full quote and analysis page.